MFAP2 and ovarian carcinoma: Considine et al. (2021) utilized extensive data from two genome-wide association studies to pinpoint protein biomarkers associated with ovarian cancer risk in circulating blood. By integrating vast proteomic and genomic datasets, they identified significant and biologically plausible associations between 26 plasma proteins, including MFAP2, and the risk of epithelial ovarian cancer. These associations remained statistically significant after controlling for false discovery rate (Considine et al., 2021).